{"id":16643,"date":"2022-03-23T09:54:17","date_gmt":"2022-03-23T09:54:17","guid":{"rendered":"https:\/\/clinlabint.com\/?p=16643"},"modified":"2022-03-23T09:54:17","modified_gmt":"2022-03-23T09:54:17","slug":"biomed-x-institute-and-boehringer-ingelheim-start-new-research-project-in-brain-sensor-development","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/biomed-x-institute-and-boehringer-ingelheim-start-new-research-project-in-brain-sensor-development\/","title":{"rendered":"BioMed X Institute and Boehringer Ingelheim start new research project in brain sensor development"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

BioMed X Institute and Boehringer Ingelheim start new research project in brain sensor development<\/h1>\/ in No Category<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

German independent research institute BioMed X has started a new research project \u2018Advanced Biomarker Detection for Pharma-cological Monitoring in the Brain\u2019 (BDB) in collaboration with Boehringer Ingelheim. The objective of the research group \u2018BDB\u2019 is to develop a continuous monitoring biosensor for direct detection of small molecule biomarkers in rodent brain tissue to support the development of innovative treatment approaches in precision psychiatry, an area of focus of Boehringer Ingelheim\u2019s R&D.<\/p>\n

<\/p>\n

\u201cThe process of developing active drugs for the treatment of neuropsychiatric diseases involves establishing a robust relationship between the pharmacodynamic effect and the pharmacokinetic parameters of new drug candidates,\u201d says Group Leader of team BDB, Dr. Khulan Sergelen. \u201cOur main task is the development of a new minimally invasive molecular biosensor, including molecular design and assay development, biocompatible sensor architecture, and optical sensor integration for in vivo monitoring.\u201d<\/p>\n

The BioMed X Institute has been working closely with Boehringer Ingelheim since 2014. \u2018Advanced Biomarker Detection for Pharma-cological Monitoring in the Brain\u2019 marks the fifth joint research project of the partners. Two projects in lung research and neuroscience have already been successfully completed and transferred to Boehringer Ingelheim for further development. Team BDB will now join two other ongoing BioMed X projects in collaboration with Boehringer Ingelheim in immunology (Pathogen-Mediated Modulation of Innate Immunity) and neuroscience (Early Intervention in Psychiatric Diseases).<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n